Sign In

Kristina Wang

Building great companies that bring transformative therapies to patients

Kristina Wang is the Director of Corporate Development and a Board Member at Apertura Gene Therapy, a biotechnology company focused on developing genetic medicines.13 She played a key role in the formation and launch of Apertura, which spun out technology into a new company with $67 million in Series A financing from Deerfield Management.2

Prior to her role at Apertura, Wang worked in Mike Greenberg's lab at Harvard Medical School, where she contributed to the development of gene regulatory elements (GREs) for modifying gene therapy expression in target cell types.4 This technology, along with a platform from the Broad Institute, forms the foundation of Apertura's approach to addressing challenges in gene therapy delivery and expression.4

Wang is committed to maximizing the impact of Apertura's platform through internal programs and partnerships with other biopharma companies and academic groups.3 She believes that Apertura's technology has the potential to unlock many new indications for gene therapy.13

Highlights

Sep 21 · aperturagtx.com
f/2: A Tale of Two Platforms – The Formation of Apertura
Sep 20 · aperturagtx.com
Apertura Gene Therapy Launches with $67M Series A Financing ...
Apertura Launches with $67 Million Financing to Improve Gene ...
Jan 1 · kristinaw.com
Kristina Wang

Related Questions

What are Kristina Wang's main responsibilities at Apertura Gene Therapy?
How did Kristina Wang transition from Noom to Apertura Gene Therapy?
What specific technologies from the Broad Institute and Harvard University is Apertura Gene Therapy utilizing?
How does Apertura Gene Therapy's platform differ from other gene therapy approaches?
What are the key challenges Kristina Wang is addressing in gene therapy?
Kristina Wang
Kristina Wang, photo 1
Kristina Wang, photo 2
Add to my network

Location

New York, New York, United States